Reports Q1 revenue $1.22M, consensus $768K. Reports cash balance of $58.0M as of March 31, which is anticipated to fund key milestones through mid-2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BOLT:
- Biotech Alert: Searches spiking for these stocks today
- Bolt Biotherapeutics to host KOL call on BDC-3042 Phase 1 results
- Bolt Biotherapeutics announces results for Boltbody ISACs at AACR meeting
- Cautious Hold Rating for Bolt Biotherapeutics Amidst Promising Developments and Uncertainties
- Bolt Biotherapeutics reports Q4 EPS (42c), consensus (35c)